Novo Nordisk and Eli Lilly bet on combination therapies for obesity and diabetes

Combination therapies against type 2 diabetes and obesity will define the market in future. This is according to the leading actors in this field, US-based Eli Lilly and Danish Novo Nordisk.

Photo: /Ritzau Scanpix/AP/Rick Bowmer/

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles